Rethinking Cell Harvesting: A Strategic Lever In Allogeneic Therapy Production

In allogeneic therapies, harvested cells are the final product—or a critical intermediate—making gentle cell separation and recovery essential to overall process performance. Losses at this stage can compromise potency, reduce yield, and introduce variability that can carry through to downstream operations. Protecting cell health while achieving high recovery is essential, especially as production scales and regulatory expectations intensify.

In this context, cell harvesting is not just a technical step but a strategic opportunity to improve product quality, process reliability, and overall manufacturing success.